Senzime exhibitor at SAMTIT

News: Uppsala, May 10, 2019. Senzime AB (publ) reports from SAMTIT Congress 8-10 May 2019

Swedish User Association for Medical Technology and IT (SAMTIT) is a cross-professional association consisting of companies, healthcare professionals with responsibility for medical technology equipment, IT and MT engineers. The reason why the association started 20 years ago was to share knowledge in the medical technology field.

“This year's congress focuses on patient safety, IT and new technology, which makes it a perfect opportunity to showcase TetraGraph for an initiated audience. Both we and our new distributor in the Nordics Vingmed exhibits TetraGraph during the event”says Pia Renaudin, CEO of Senzime

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com       

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se,  is Certified Adviser for Senzime. www.senzime.com 

Tags:

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com

Subscribe

Media

Media

Documents & Links

Quotes

“This year's congress focuses on patient safety, IT and new technology, which makes it a perfect opportunity to showcase TetraGraph for an initiated audience. Both we and our new distributor in the Nordics Vingmed exhibits TetraGraph during the event”
Pia Renaudin, CEO at Senzime